Principles of use of surrogate markers and endpoints

Maturitas

Volumn 47, Issue 4, 2004, Pages 293-298

  Kluft, C ^a  

^a TNO   (Netherlands)

Author keywords

Biomarkers; Cardiovascular disease; Haemostasis; Hormone replacement therapy; Oral contraceptives; Surrogate marker; Thrombosis

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; MOLECULAR MARKER; SEX HORMONE; SEX HORMONE BINDING GLOBULIN;

ARTERY THROMBOSIS; ATHEROGENESIS; ATHEROSCLEROSIS; BLOOD CLOTTING; CARDIOVASCULAR EFFECT; COMPUTER MODEL; CONFERENCE PAPER; DISEASE MARKER; DRUG EFFECT; DRUG INDUCED DISEASE; DRUG MECHANISM; EXPERIMENTAL ANIMAL; EXPERIMENTAL MODEL; HORMONAL CONTRACEPTION; HORMONE SUBSTITUTION; HUMAN; MOLECULAR DYNAMICS; NONHUMAN; QUANTITATIVE ANALYSIS; RISK FACTOR; STATISTICAL ANALYSIS; VALIDATION PROCESS; VENOUS THROMBOEMBOLISM;

BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CONTRACEPTIVES, ORAL, COMBINED; DATA INTERPRETATION, STATISTICAL; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; RISK;

EID: 1942471868     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.maturitas.2003.11.011     Document Type: Conference Paper

References (24)

1. NIH-FDA Conference: Biomarkers and Surrogate Endpoints: Advancing clinical research and applications. Dis Markers 1998;14:187-334.
2. Lesko L.J., Atkinson A.J. Jr. Use of biomarkers and surrogate endpoints in drug development and regulatory decision making: criteria, validation, strategies. Annu. Rev. Pharmacol. Toxicol. 41:2001;347-366.
3. Kluft C., Iacoviello L. Genetics of myocardial infarction: haemocoagulative aspects. Cardiologia. 42(S3):1997;697-700.
4. Manten B., Westendorp R.G., Koster T., Reitsma P.H., Rosendaal F.R. Risk factor profiles in patients with different clinical manifestations of venous thromboembolism: a focus on the factor V Leiden mutation. Thromb. Haemost. 76:1996;510-513.
5. Lewis M.A. The transnational study on oral contraceptives and the health of young women. Methods, results, new analyses and the healthy user effect. Hum. Reprod. Updat. 5:1999;707-720.
6. Hulley S., Grady D., Bush T., Furberg C., Herrington D., Riggs B.et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/Progestin Replacement Study (HERS) Research Group. JAMA. 280:1998;605-613.
7. Writing group for the Women's Health Initiative investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002;288:321-33.
8. Clarkson T.B. The new conundrum: do estrogens have any cardiovascular benefits? Int. J. Fertil. Womens Med. 47:2002;61-68.
9. Hockin M.F., Jones K.C., Everse S.J., mann K.G. A model for the stoichiometric regulation of blood coagulation. J. Biol. Chem. 277:2002;18322-18333.
10. Vandenbroucke J.P., Koster T., Briet E., Reitsma P.H., Bertina R.M., Rosendaal F.R. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet. 344:1994;1453-1457.
11. Martinelli I., Sacchi E., Landi G., Taioli E., Duca F., Mannucci P.M. High risk of cerebral-vein thrombosis in carriers of a prothrombin-gene mutation and in users of oral contraceptives. N. Engl. J. Med. 338:1998;1793-1797.
12. MacMahon S., Peto R., Cutler J., Collins R., Sorlie P., Neaton J.et al. Blood pressure, stroke, and coronary heart disease. Lancet. 335:1990;765-774.
13. Folsom A.R., Aleksic N., Wang L., Cushman M., Wu K.K., White R.H. Protein C, antithrombin, and venous thromboembolism incidence. A prospective population-based study. Arterioscler. Thromb. Vasc. Biol. 22:2002;1018-1022.
14. Butenas S., Veer van't C., Mann K.G. Normal thrombin generation. Blood. 94:1999;2169-2178.
15. Spek C.A., Koster T., Rosendaal F.R., Bertina R.M., Reitsma P.H. Genotypic variation in the promoter region of the protein C gene is associated with plasma protein C levels and thrombotic risk. Arterioscler. Thromb. Vasc. Biol. 15:1995;214-218.
16. Odlind V., Milsom I., Persson I., Victor A. Can changes in sex hormone binding globulin predict the risk of venous thromboembolism with combined oral contraceptive pills. Acta Obstet. Gynecol. Scand. 81:2002;482-490.
17. Kluft C. Is C-reactive protein an additional, surrogate end-point for statin treatment? Eur. Heart J. 23:2002;761-764.
18. Kleemann R., Gervois P.P., Verschuren L., Staels B., Princen H.M., Kooistra T. Fibrates down-regulate IL-1-stimulated C-reactive protein gene expression in hepatocytes by reducing nuclear p50-NFkappa B-C/EBP-beta complex formation. Blood. 101:2003;545-551.
19. Kluft C. Pro-inflammatory effects of oestrogens. Fibrinolysis Proteolysis. 13:1999;217-219. [Editorial].
20. Kluft C. HRT effects on inflammatory markers: is chronic inflammation a contra-indication for HRT? Int. Congress Ser. 1229:2002;103-108.
21. Bloemenkamp K.W.M., Rosendaal F.R., Helmerhorst F.M., Koster T., Bertina R.M., Vandenbroucke J.P. Hemostatic effects of oral contraceptives in women who developed deep-vein thrombosis while using oral contraceptives. Thromb. Haemost. 80:1998;382-387.
22. Kemmeren J.M., Algra A., Meijers J.C., Bouma B.N., Grobbee D.E. Effects of second and third generation oral contraceptives and their respective progestagens on the coagulation system in the absence or presence of the factor V Leiden mutation. Thromb. Haemost. 87:2002;199-205.
23. Herrington D.M., Howard T.D., Hawkins G.A., Reboussin D.M., Xu J., Zheng S.L.et al. Estrogen receptor polymorphisms and effects of estrogen replacement on HDL cholesterol in women with coronary disease. N. Engl. J. Med. 346:2002;967-975.
24. Herrington D.M., Howard T.D., Brosnihan K.B., McDonnell D.P., Li X., Hawkins G.A.et al. Common estrogen receptor polymorphism augments effects of hormone replacement therapy on E-selectin but not on C-reactive protein. Circulation. 105:2002;1879-1882.